Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma (Q39330252)

11 September 2017

title

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma (English)

1 reference

11 September 2017

Munmun Rahman

1

1 reference

11 September 2017

Kentaro Nakayama

2

1 reference

11 September 2017

Mohammed Tanjimur Rahman

3

1 reference

11 September 2017

Naomi Nakayama

4

1 reference

11 September 2017

Masako Ishikawa

5

1 reference

11 September 2017

Atsuko Katagiri

6

1 reference

11 September 2017

Kouji Iida

7

1 reference

11 September 2017

Satoru Nakayama

8

1 reference

11 September 2017

Yoshiro Otsuki

9

1 reference

11 September 2017

Ie-Ming Shih

10

1 reference

11 September 2017

Kohji Miyazaki

11

1 reference

11 September 2017

publication date

15 June 2012

1 reference

https://api.elsevier.com/content/article/PII:S0046817712000913?httpAccept=text/xml

11 September 2017

language of work or name

English

0 references

work available at URL

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

https://api.elsevier.com/content/article/PII:S0046817712000913?httpAccept=text/plain

4 January 2025

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

4 January 2025

1 reference

11 September 2017

volume

43

1 reference

11 September 2017

issue

12

1 reference

11 September 2017

page(s)

2197-2206

1 reference

Mutations of the BRAF gene in human cancer

11 September 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE00766

Cancer statistics, 2012

1

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

4 January 2025

Ovarian cancer

2

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

4 January 2025

3

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

4 January 2025

4

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

4 January 2025

5

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Ovarian clear cell adenocarcinoma

4 January 2025

7

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Ovarian atypical endometriosis: its close association with malignant epithelial tumours

4 January 2025

8

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon

4 January 2025

9

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary

4 January 2025

10

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases

4 January 2025

11

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

4 January 2025

12

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

4 January 2025

13

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

ARID1A mutations in endometriosis-associated ovarian carcinomas

4 January 2025

14

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma

4 January 2025

15

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Mutation of the PIK3CA gene in ovarian and breast cancer

4 January 2025

16

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas

4 January 2025

17

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

4 January 2025

18

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

High frequency of mutations of the PIK3CA gene in human cancers

4 January 2025

19

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

PI3K pathway alterations in cancer: variations on a theme

4 January 2025

20

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Diverse tumorigenic pathways in ovarian serous carcinoma

4 January 2025

21

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

4 January 2025

22

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

4 January 2025

24

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines

4 January 2025

26

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss

4 January 2025

27

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

4 January 2025

28

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage

4 January 2025

29

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

PIK3CA mutations in breast cancer are associated with poor outcome

4 January 2025

30

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women

4 January 2025

31

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

4 January 2025

32

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma

4 January 2025

33

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers

4 January 2025

34

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma

4 January 2025

35

1 reference

https://api.crossref.org/works/10.1016/J.HUMPATH.2012.03.011

4 January 2025

Identifiers

1 reference

11 September 2017

1 reference